| Name | Title | Contact Details |
|---|---|---|
Kim Warren |
Chief Technology Officer | Profile |
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Intellikine is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avitide is dedicated to advancing our partners’ clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.
Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interact Medical is a South Bend, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.